Related Experiment Video

Updated: Jul 19, 2026

Assay Development for High-Throughput Drug Screening Against Mycobacteria
07:50

Assay Development for High-Throughput Drug Screening Against Mycobacteria

Published on: October 25, 2024

Current pharmacotherapy for the treatment of crescentic glomerulonephritis

Frederick W K Tam1

  • 1Imperial College London, Renal Section, Division of Medicine, West London Renal and Transplant Centre, Hammersmith Hospital, Du Cane Road, London W12 0NN, UK. f.tam@imperial.ac.uk

Expert Opinion on Investigational Drugs
|October 17, 2006
PubMed

Insights

Crescentic glomerulonephritis, a severe kidney disease, can lead to rapid renal failure. Current treatments face challenges, but new targeted therapies and biomarkers show promise for improved patient outcomes.

Area of Science:

  • Nephrology
  • Immunology
  • Renal Medicine

Background:

  • Glomerulonephritis is a significant cause of end-stage renal disease.
  • Crescentic glomerulonephritis (CGN) is a severe form, leading to rapid renal failure if untreated.
  • Current immunotherapies (corticosteroids, cytotoxic drugs, plasma exchange) have limitations.

Purpose of the Study:

  • To review current challenges and future opportunities in treating crescentic glomerulonephritis.
  • To highlight advancements in targeted therapies and noninvasive biomarkers for CGN management.

Main Methods:

  • Review of existing literature on glomerulonephritis and crescentic glomerulonephritis.
  • Discussion of current therapeutic strategies and their limitations.
  • Exploration of emerging targeted therapies and diagnostic biomarkers.

Main Results:

  • CGN poses significant treatment challenges, including therapy toxicity and relapse prevention in specific conditions like ANCA-associated vasculitis and IgA nephropathy.
  • Potential for novel therapies targeting immune cells (T cells, B cells) and cytokines.
  • Urinary cytokine measurement emerges as a noninvasive biomarker for monitoring disease activity and prognosis.

Conclusions:

  • Effective treatment of CGN requires addressing current therapeutic challenges.
  • Targeted therapies and noninvasive biomarkers represent promising avenues for improving CGN management and patient outcomes.
  • Further controlled clinical trials are essential to establish the efficacy and safety of novel approaches.

More Related Videos

Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway07:15

Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway

Published on: August 23, 2024

Related Concept Videos

Acute Pyelonephritis II: Diagnostic Studies and Management01:28

Acute Pyelonephritis II: Diagnostic Studies and Management

Introduction:For diagnosing acute pyelonephritis, a comprehensive patient history is collected to identify symptoms such as dysuria, frequent or urgent urination, flank pain, or costovertebral angle (CVA) tenderness that may suggest a kidney infection.Physical ExaminationDuring the physical examination, CVA tenderness is assessed. This involves gentle percussion over the costovertebral angle, where tenderness often indicates a kidney infection.Diagnostic TestsUrinalysis: Used to identify white...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...
Nephrotic Syndrome III : Nursing Management01:24

Nephrotic Syndrome III : Nursing Management

Nursing management for nephrotic syndrome adapts as the disease progresses, with strategies evolving to address advancing symptoms and complications.Early-Stage Management In the early stages, nursing interventions for nephrotic syndrome resemble those used in managing acute glomerulonephritis, focusing on symptom monitoring, fluid balance, and managing mild to moderate edema.Vital Signs: Regularly monitor blood pressure, pulse, respiratory rate, and temperature to promptly identify...
Streptococcal Pharyngitis01:27

Streptococcal Pharyngitis

Streptococcal pharyngitis, commonly known as “strep throat,” is an acute infection of the oropharyngeal tissues caused by the Gram‑positive Group A Streptococcus (Streptococcus pyogenes). Transmission occurs primarily through respiratory droplets expelled during coughing, sneezing, or talking.Mechanisms of Host Entry and Immune EvasionUpon entering the host, S. pyogenes adheres to the mucosal epithelial cells of the pharynx via surface proteins, notably lipoteichoic acid and the antiphagocytic...